Ian Roullier is the co-founder of the Psychedelic Participant Advocacy Network (PsyPAN). Ian’s participation in clinical trials run by Imperial College (2015) and King’s College/Compass Pathways (2019), both examining the effect of psilocybin on depression, naturally led to his dedication to helping bring these treatments safely to all who may benefit from them. PsyPAN works with organisations providing psychedelic-assisted therapy with the aim of helping create a sector-wide model of best practice with participant wellbeing placed at its heart, and also aims to provide much-needed community and connection for people who have received these treatments.